Efficacy of <i>Clostridium butyricum</i> preparation concomitantly with <i>Helicobacter pylori</i> eradication therapy in relation to changes in the intestinal microbiota

Imase, Kyoto; Takahashi, Motomichi; Tanaka, Akifumi; Tokunaga, Kazutoshi; Sugano, Hajime; Tanaka, Mamoru; Ishida, Hideyuki; Kamiya, Shigeru; Takahashi, Shinichi

doi:10.1111/j.1348-0421.2008.00026.x

Cited by 69 publications

(53 citation statements)

References 31 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To clarify the duration of this effect, Buhling et al [90] showed that the eradication therapy exerted only a short-term influence on gut flora, whereas another study observed long-term disturbances even 9 weeks after treatment was complete. Probiotics, defined as microorganisms with potentially beneficial health effects, such as Lactobacilli, is assumed to prevent or at least partly diminish the microbial disturbances [89,92]. Probiotics, defined as microorganisms with potentially beneficial health effects, such as Lactobacilli, is assumed to prevent or at least partly diminish the microbial disturbances [89,92].…”

Section: H Pylori Eradication and The Alterations Of Microbiotamentioning

confidence: 99%

Imbalance of Gastrointestinal Microbiota in the Pathogenesis ofHelicobacter pylori‐Associated Diseases

Yang

Lü

2016

Helicobacter

View full text Add to dashboard Cite

The development of new nucleotide sequencing techniques and advanced bioinformatics tools has opened the field for studying the diversity and complexity of the gastrointestinal microbiome independent of traditional cultural methods. Owing largely to the gastric acid barrier, the human stomach was long thought to be sterile. The discovery of Helicobacter pylori, the gram-negative bacterium that infects upwards of 50% of the global population, has started a major paradigm shift in our understanding of the stomach as an ecologic niche for bacteria. Recent sequencing analysis of gastric microbiota showed that H. pylori was not alone and the interaction of H. pylori with those microorganisms might play a part in H. pylori-associated diseases such as gastric cancer. In this review, we summarize the available literature about the changes of gastrointestinal microbiota after H. pylori infection in humans and animal models, and discuss the possible underlying mechanisms including the alterations of the gastric environment, the secretion of hormones and the degree of inflammatory response. In general, information regarding the composition and function of gastrointestinal microbiome is still in its infancy, future studies are needed to elucidate whether and to what extent H. pylori infection perturbs the established microbiota. It is assumed that clarifying the role of gastrointestinal communities in H. pylori-associated diseases will provide an opportunity for translational application as a biomarker for the risk of serious H. pylori diseases and perhaps identify specific organisms for therapeutic eradication.

show abstract

Section: H Pylori Eradication and The Alterations Of Microbiotamentioning

confidence: 99%

Imbalance of Gastrointestinal Microbiota in the Pathogenesis ofHelicobacter pylori‐Associated Diseases

Yang

Lü

2016

Helicobacter

View full text Add to dashboard Cite

show abstract

“…All patients with influenza virus H7N9 infection showed a sharp increase in inflammatory markers in the blood, caused by the primary and secondary infections. There are many reports of anti-inflammatory activity of probiotics, including CBM588 [10,33]. With regard to the assessment of microecological treatment strategies, treatment of H7N9 infection has previously focused on pathogenicity because of the translocation and virulence of probiotics [34], and conflict between antibiotics that kill bacteria and microecological regulatory agents that promote bacterial growth, so that the negative effects did not outweigh the benefits.…”

Section: Discussionmentioning

confidence: 99%

“…CBM588 ( Clostridium butyricum 588 strain MIYA-BM tablets; Miyarisan Pharmaceutical, Tokyo, Japan) prevents antibiotic-associated diarrhea [10] and has anti-inflammatory effects in the colon as a result of butyric acid production [11]. We retrospectively assessed the effects of microbiota restoration strategies on restoring intestinal homeostasis under antibiotic exposure, and on reducing the risk of secondary infection, by real-time monitoring of the shift in predominant intestinal bacteria using quantitative polymerase chain reaction (qPCR) and PCR-based denaturing gradient gel electrophoresis (PCR-DGGE).…”

Section: Introductionmentioning

confidence: 99%

An analysis of microbiota-targeted therapies in patients with avian influenza virus subtype H7N9 infection

et al. 2014

View full text Add to dashboard Cite

BackgroundSelective prophylactic decontamination of the digestive tract is a strategy for the prevention of secondary nosocomial infection in patients with avian influenza virus subtype H7N9 infection. Our aim was to summarize the effectiveness of these therapies in re-establishing a stable and diverse microbial community, and reducing secondary infections.MethodsComprehensive therapies were dependent on the individual clinical situation of subjects, and were divided into antiviral treatment, microbiota-targeted therapies, including pro- or pre-biotics and antibiotic usage, and immunotherapy. Quantitative polymerase chain reaction and denaturing gradient gel electrophoresis (DGGE) were used for real-time monitoring of the predominant intestinal microbiome during treatment. Clinical information about secondary infection was confirmed by analyzing pathogens isolated from clinical specimens.ResultsDifferent antibiotics had similar effects on the gut microbiome, with a marked decrease and slow recovery of the Bifidobacterium population. Interestingly, most fecal microbial DGGE profiles showed the relative stability of communities under the continual suppression of the same antibiotics, and significant changes when new antibiotics were introduced. Moreover, we found no marked increase in C-reactive protein, and no cases of bacteremia or pneumonia, caused by probiotic use in the patients, which confirmed that the probiotics used in this study were safe for use in patients with H7N9 infection. Approximately 72% of those who subsequently suffered exogenous respiratory infection by Candida species or multidrug-resistant Acinetobacter baumannii and Klebsiella pneumoniae were older than 60 years. The combination of probiotics and prebiotics with antibiotics seemed to fail in these patients.ConclusionsElderly patients infected with the influenza A (H7N9) virus are considered a high-risk group for developing secondary bacterial infection. Microbiota restoration treatment reduced the incidence of enterogenous secondary infection, but not exogenous respiratory infection. The prophylactic effects of microbiota restoration strategies for secondary infection were unsatisfactory in elderly and critically ill patients.

show abstract

“…Several studies evaluated whether probiotic supplementation might help to prevent or reduce drug‐related side effects during H. pylori eradication therapy in adults [61,63,64,66,68,69,72–75,78–80]. All showed that diarrhea, nausea and taste disturbances were significantly reduced by probiotics and overall they were superior to placebo for side effect prevention.…”

Section: Clinical Studiesmentioning

confidence: 99%

Role of Probiotics in Pediatric Patients with Helicobacter pylori Infection: A Comprehensive Review of the Literature

et al. 2010

View full text Add to dashboard Cite

Background: The current guidelines suggest the use of triple therapy as first choice treatment of Helicobacter pylori infection, although the eradication failure rate is more than 30%. Current interest in probiotics as therapeutic agents against H. pylori is stimulated not only by the clinical data showing efficacy of some probiotics in different gastrointestinal diseases but also by the increasing resistance of pathogenic bacteria to antibiotics, thus the interest for alternative therapies is a real actual topic. Aim: To review in vitro and in vivo studies on the role of probiotics in H. pylori infection focusing on the paediatric literature. Materials and methods: Pre‐clinical and clinical paediatric studies in English assessing the role of probiotics in H. pylori infection identified by MEDLINE search (1950–2009) were reviewed. Results: In vitro studies demonstrated an inhibitory activity of probiotics on H. pylori growth and that this effect is extremely strain specific. Available data in children indicate that probiotics seems to be efficacious for the prevention of antibiotic associated side‐effects, and might be of help for the prevention of H. pylori complications by decreasing H. pylori density and gastritis, and for the prevention of H. pylori colonization or re‐infection by inhibiting adhesion to gastric epithelial cells. There is no clear evidence that probiotics may increase the H. pylori eradication rate. Conclusion: Both in vitro and in vivo studies provide evidence that probiotics may represent a novel approach to the management of H. pylori infection.

show abstract

Efficacy of Clostridium butyricum preparation concomitantly with Helicobacter pylori eradication therapy in relation to changes in the intestinal microbiota

Cited by 69 publications

References 31 publications

Imbalance of Gastrointestinal Microbiota in the Pathogenesis ofHelicobacter pylori‐Associated Diseases

Imbalance of Gastrointestinal Microbiota in the Pathogenesis ofHelicobacter pylori‐Associated Diseases

An analysis of microbiota-targeted therapies in patients with avian influenza virus subtype H7N9 infection

Role of Probiotics in Pediatric Patients with Helicobacter pylori Infection: A Comprehensive Review of the Literature

Contact Info

Product

Resources

About